-+ 0.00%
-+ 0.00%
-+ 0.00%

IceCure Submits Filing For Regulatory Approval Of Its Next-Generation XSense Cryoablation System In Israel

Benzinga·02/24/2025 13:39:12
Listen to the news

Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing demand 

CAESAREA, Israel, Feb. 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has filed for regulatory approval with the Medical Device Division ("AMAR") of Israel's Ministry of Health for its next-generation single cryoprobe cryoablation system, the XSense™ System and CryoProbes.